What is GHRP-6?

GHRP-6 is a synthetic growth hormone-releasing peptide that acts as a ghrelin/GHS receptor agonist. It stimulates pituitary GH release and is part of the older GHRP family that includes GHRP-6, GHRP-2, hexarelin, and ipamorelin. [17][15][34]

GHRP-6 is distinguished by pronounced appetite stimulation and more ACTH/cortisol/prolactin activity than cleaner GH secretagogues. [15][16]

GHRP-6 is one of the older growth hormone-releasing hexapeptides. The “6” refers to its hexapeptide structure, not a sixth-generation product, and it should be distinguished from GHRP-2, hexarelin, ipamorelin, and GHRH fragments. [34][17]

What GHRP-6 is investigated for

GHRP-6 evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

GH release and IGF-1 response

Injectable

56% Emerging

GHRP-6 is best framed as a GH secretagogue with limited long-term outcome evidence. [17][15][16][20][21][22]

Human evidence

Human studies support acute GH, ACTH, cortisol, and pharmacokinetic responses, but long-term fat-loss, lean-mass, cachexia, or wellness outcomes are not established. [17][15][16]

Animal / mechanistic evidence

Ghrelin/GHS receptor biology supports pituitary GH release and related endocrine effects. [17][15][16]

Appetite stimulation

Injectable

48% Preliminary

Appetite stimulation can be useful in wasting contexts or undesirable for fat-loss goals, so it should be presented as a goal-dependent effect. [15][16]

Human evidence

Human endocrine studies support GHRP-6 as a ghrelin-receptor secretagogue, but controlled human appetite-endpoint evidence remains limited. [15][16]

Animal / mechanistic evidence

Ghrelin-receptor biology directly supports appetite signaling and makes appetite stimulation a plausible GHRP-6 effect. [15][16]

Gastric motility

Injectable

30% Limited

Gastric-motility positioning is model-supported and should not be treated as a validated GI therapy. [41][43]

Human evidence

No controlled human trial establishes GHRP-6 as a treatment for gastroparesis, ileus, or delayed gastric emptying. [41][42]

Animal / mechanistic evidence

Mouse and rat studies report prokinetic gastric-emptying and intestinal-transit effects through ghrelin-receptor pathways. [41][42][43]

Fat loss, lean mass, and recovery

Injectable

28% Limited

Fat-loss, lean-mass, and recovery claims remain extrapolated from GH-axis pharmacology and preclinical injury models. [17][20]

Human evidence

Human GH-release and pharmacokinetic studies do not establish durable fat-mass, lean-mass, recovery, or cachexia outcomes. [17][15][16]

Animal / mechanistic evidence

Preclinical studies support tissue-injury, cardiac, lung, kidney, and skeletal-muscle hypotheses, but these remain model-based. [20][21][22][23]

Evidence snapshot

Overall confidence

Emerging

54%

GHRP-6 has human endocrine pharmacology and a substantial GH-secretagogue literature. The limiting issue is absent approved use and weak long-term outcome evidence for common wellness claims. [17][15][16]

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

54%

Human evidence

Emerging

Available human studies support acute GH, ACTH, cortisol, and pharmacokinetic responses. Long-term body-composition, cachexia, and wellness outcomes are not established. [17][15][16]

46%

Animal / preclinical

Preliminary

Preclinical studies support tissue-injury, cardiac, lung, kidney, and skeletal-muscle hypotheses. These remain model-based signals, not validated treatment outcomes. [20][21][22]

65%

Mechanism support

Moderate

Ghrelin/GHS receptor activation directly explains GH release, appetite effects, and off-target endocrine monitoring. Mechanistic confidence is stronger than outcome confidence. [15][16]

Forms & administration

GHRP-6 is usually discussed as a short-acting injectable GH-axis protocol. Timing, food spacing, appetite effects, and lab context matter because the goal is a GH pulse. [17][15][16]

Injectable

Dosing & protocols

The notes below separate published trial design from commonly discussed cosmetic or compounded-use patterns. They are educational context only, not a prescription or product instruction.

Typical Range

Common injectable protocols use 100-300 mcg per dose. [17][15][16]

Frequency

2-3 times daily is the common app schedule because the peptide is short acting. [17][15][16]

Timing Considerations

Timing is commonly morning, pre-workout, or before bed; pre-meal timing is used when appetite stimulation is the goal. Food timing matters because insulin and amino acids can blunt GH pulse interpretation. [17][15][16]

Cycle Length

Common cycles run 8-12 weeks. IGF-1, fasting glucose, water retention, appetite, sleep, and training notes are the usual reassessment points. [17][15][16]

What to expect

First week

Injectable GH-pulse use may first show stronger hunger, sleep changes, water retention, or shifts in training-day recovery. [15][16]

Weeks 4-8

Appetite pattern, waist, training tolerance, recovery notes, IGF-1, and fasting glucose become clearer once timing and food windows are consistent. [17][15][16]

After stopping

Appetite, water retention, and IGF-1-related markers often drift toward baseline after short-acting GH secretagogue exposure ends. [17][15][34]

Safety profile

Injectable GHRP-6 safety centers on hunger, water retention, glucose and IGF-1 effects, ACTH/cortisol/prolactin biology, injection quality, pregnancy avoidance, active malignancy caution, and sports prohibition. [17][15][16][36][38]

Common side effects

Hunger [15][16]
Water retention [17][15][16]

Cautions

Glucose monitoring [17][15][16][36][38]
ACTH/cortisol/prolactin effects [15][16]
Active malignancy [17][15][16][36][38]
Sports prohibited [40]

Who GHRP-6 is not for

Route-specific avoid and medical-review notes:

Active or recent cancer
Avoid outside specialist-directed care because GH/IGF-1 pathway stimulation can be inappropriate in malignancy contexts. [17][15][16][36][38]
Pregnancy or breastfeeding
Avoid because reproductive and lactation safety are not established for unapproved GH secretagogue use. [17][15][16][36][38]
Acromegaly or GH excess
Do not add GH secretagogue stimulation when GH/IGF-1 excess is present or suspected. [17][15][16][36][38]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

Diabetes medications
Diabetes medications can become harder to adjust when injectable GH-axis stimulation shifts glucose control; this is a theoretical GH/insulin-axis caution. [17][15][16][36][38]
Other GH-axis agents
GHRH analogs, GHRPs, or HGH can add overlapping IGF-1, water-retention, glucose, and sports-risk concerns with injectable GHRP-6; this is a stack-level safety caution. [17][15][16][36][38]

Regulatory status

United States

GHRP-6 has no FDA-approved injectable U.S. use as of 2026-06-21. FDA warning-letter materials also state GHRP-6 was not eligible for 503A exemptions in that context because it was not on the bulks list or an approved-drug component. [36][38]

Route	FDA drug approval	503A compounding
Injectable	Not Approved As of 2026-06-21, GHRP-6 was not FDA-approved as an injectable drug. FDA warning-letter context also separates 503A eligibility from FDA drug approval. [36][38]	Not Listed FDA warning-letter materials state that GHRP-6 did not appear on the 503A Bulks List, was not an FDA-approved drug component, and had not been nominated with adequate support for FDA to evaluate it. [38]

Injectable

FDA drug approval

Not Approved

As of 2026-06-21, GHRP-6 was not FDA-approved as an injectable drug. FDA warning-letter context also separates 503A eligibility from FDA drug approval. [36][38]

503A compounding

Not Listed

FDA warning-letter materials state that GHRP-6 did not appear on the 503A Bulks List, was not an FDA-approved drug component, and had not been nominated with adequate support for FDA to evaluate it. [38]

International

EU/Europe, UK, Canada, and Australia should be checked by local medicine and compounding rules; any non-U.S. diagnostic or research context should not be generalized to therapeutic approval.

Sports & competition

WADA's 2026 Prohibited List treats GHRPs and growth hormone secretagogues as S2-prohibited; tested athletes should treat injectable GHRP-6 use as prohibited without a valid TUE. [40]

How it works

GHRP-6 is an older ghrelin/GHS receptor agonist that can stimulate pituitary GH release after injection. Human pharmacokinetic and endocrine studies also connect it with ACTH and cortisol responses, which is why it is not just a clean GH pulse in practical interpretation. [17][15]

The mechanism helps explain appetite and metabolic-monitoring concerns. Downstream GH and IGF-1 signaling can interact with glucose and fluid retention, while ghrelin-receptor activity can affect hunger; none of that establishes durable body-composition, recovery, sleep, or longevity benefit in people. [17][15][16]

Research gaps & open questions

What the current literature has not yet settled about GHRP-6:

Long-term body-composition, recovery, sleep, glucose, IGF-1, cortisol, and prolactin outcomes need controlled human study. [17][15][16]

Head-to-head comparisons among GHRPs should use outcomes and tolerability, not only GH pulse height. [15][16]

Sports detection and contamination risk need to be considered in any athlete-facing protocol. [40]

Common questions

Is GHRP-6 FDA-approved?

No. GHRP-6 has no FDA-approved injectable U.S. use, and it is not on the 503A Bulks List. [36][38]

Is GHRP-6 banned in tested sports?

Yes. WADA treats GHRPs and GH secretagogues such as GHRP-6 as S2-prohibited without a valid TUE. [40]

What makes GHRP-6 different?

GHRP-6 stands out for appetite stimulation plus more ACTH, cortisol, and prolactin activity than cleaner GH-secretagogue profiles. [15][16]

Myths & misconceptions

Myth

GHRP-6 is undetectable because it clears quickly.

Reality

Short plasma exposure does not mean no sports-detection risk; WADA class rules and urine metabolite methods matter. [40]

Myth

GHRP-6 is safe because it stimulates natural GH.

Reality

Stimulating endogenous GH is still pharmacologic and can affect appetite, glucose, water retention, IGF-1, cortisol, or prolactin depending on the compound. [17][15][16]

History & discovery

GHRP-6 is one of the older synthetic GH-releasing peptides, important because it helped define how ghrelin/GHS-receptor agonists amplify pituitary GH pulses and appetite-linked endocrine signaling. [17][15][34]

Early work showed maximal GH stimulation depended on endogenous GHRH, helping place GHRP-6 in the secretagogue pathway rather than direct hormone replacement. [34]

Volunteer and disease-context studies measured pharmacokinetics, GH, ACTH, and cortisol responses, giving GHRP-6 more human pharmacology than many research peptides. [17][15][16]

Anti-doping rules later made GHRP-6 a prohibited GH secretagogue, while U.S. regulatory materials kept it outside approved injectable-drug status. [40][36][38]

Published research 40 studies

[1]

Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of Hexarelin and GHRP-2 in humans.

Journal of endocrinological investigation, 1999 Feb. human clinical.

[2]

Growth hormone (GH) response to GH-releasing peptide-6 and GH-releasing hormone in normal-weight and overweight patients with non-insulin-dependent diabetes mellitus.

Metabolism: clinical and experimental, 1999 Apr. human clinical.

[3]

Acute dexamethasone administration enhances GH responsiveness to GH releasing peptide-6 (GHRP-6) in man.

Clinical endocrinology, 1999 Oct. human clinical.

[4]

Effects of fasting and pegvisomant on the GH-releasing hormone and GH-releasing peptide-6 stimulated growth hormone secretion.

Clinical endocrinology, 2001 Oct. human clinical.

[5]

Effects of growth hormone-releasing peptides in healthy dogs and in dogs with pituitary-dependent hyperadrenocorticism.

Molecular and cellular endocrinology, 2002 Nov 29. animal.

[6]

GHRP-6 is able to stimulate cortisol and ACTH release in patients with Cushing's disease: comparison with DDAVP.

Journal of endocrinological investigation, 2003 Mar. human clinical.

[7]

Growth hormone response to GHRH + GHRP-6 in type 2 diabetes during euglycemic and hyperglycemic clamp.

Diabetes research and clinical practice, 2004 Jan. human clinical.

[8]

Hexarelin decreases slow-wave sleep and stimulates the secretion of GH, ACTH, cortisol and prolactin during sleep in healthy volunteers.

Psychoneuroendocrinology, 2004 Aug. human clinical.

[9]

Decreased GH secretion and enhanced ACTH and cortisol release after ghrelin administration in Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH.

Pituitary, 2006. human clinical.

[10]

Decreased ghrelin-induced GH release in thyrotoxicosis: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH.

Pituitary, 2007. human clinical.

[11]

Association between tumoral GH-releasing peptide receptor type 1a mRNA expression and in vivo response to GH-releasing peptide-6 in ACTH-dependent Cushing's syndrome patients.

European journal of endocrinology, 2008 May. human clinical.

[12]

Ghrelin and GHRP-6-induced ACTH and cortisol release in thyrotoxicosis.

Pituitary, 2009. human clinical.

[13]

Adrenocorticotrophic hormone (ACTH) responsiveness to ghrelin increases after 6 months of ketoconazole use in patients with Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6).

Clinical endocrinology, 2010 Jan. human clinical.

[14]

Diagnosis of adrenal insufficiency using the GHRP-6 Test: comparison with the insulin tolerance test in patients with hypothalamic-pituitary-adrenal disease.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2010 Mar. human clinical.

[15]

Effects of ghrelin, growth hormone-releasing peptide-6, and growth hormone-releasing hormone on growth hormone, adrenocorticotropic hormone, and cortisol release in type 1 diabetes mellitus.

Metabolism: clinical and experimental, 2010 Oct. human clinical.

[16]

Effects of ghrelin, GH-releasing peptide-6 (GHRP-6) and GHRH on GH, ACTH and cortisol release in hyperthyroidism before and after treatment.

Pituitary, 2010 Dec. human clinical.

[17]

Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2013 Jan 23. human clinical.

[18]

Role of epidermal growth factor and growth hormone-releasing peptide-6 in acceleration of renal tissue repair after kanamycin overdosing in rats.

Iranian journal of kidney diseases, 2014 Sep. animal.

[19]

[D-Lys3]-GHRP-6 exhibits pro-autophagic effects on skeletal muscle.

Molecular and cellular endocrinology, 2015 Feb 5. review.

[20]

Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms.

Frontiers in pharmacology, 2024. review.

[21]

Growth hormone-releasing peptide 6 (GHRP-6) hydrogel for acute kidney injury therapy via metabolic regulation.

Journal of nanobiotechnology, 2025 Dec 1. review.

[22]

Growth hormone releasing peptide-6 (GHRP-6) ameliorates acute lung injury and its subsequent evolvement to interstitial fibrosis.

International immunopharmacology, 2026 Mar 1. review.

[23]

Growth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation.

Pharmaceuticals (Basel, Switzerland), 2026 Mar 12. review.

[24]

Comparison of the effects of growth hormone-releasing hormone and hexarelin, a novel growth hormone-releasing peptide-6 analog, on growth hormone secretion in humans with or without glucocorticoid excess.

The Journal of endocrinology, 1995 Aug. human clinical.

[25]

The effect of an opiate antagonist on the hormonal changes induced by hexarelin.

Clinical endocrinology, 1995 Sep. human clinical.

[26]

Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man.

Neuroendocrinology, 1995 May. human clinical.

[27]

Growth hormone secretion after the administration of GHRP-6 or GHRH combined with GHRP-6 does not decline in late adulthood.

Clinical endocrinology, 1995 Feb. human clinical.

[28]

Hexarelin, a synthetic growth hormone releasing peptide, stimulates prolactin secretion in acromegalic but not in hyperprolactinaemic patients.

Clinical endocrinology, 1996 Jan. human clinical.

[29]

Evaluation of pituitary GH reserve with GHRP-6.

Journal of pediatric endocrinology & metabolism : JPEM, 1996 Jun. review.

[30]

Growth hormone releasing hexapeptide-6 (GHRP-6) test in the diagnosis of GH-deficiency.

Journal of pediatric endocrinology & metabolism : JPEM, 1996 Jun. review.

[31]

Influence of endogenous cholinergic tone and growth hormone-releasing peptide-6 on exercise induced growth hormone release.

Clinical endocrinology, 1997 Feb. human clinical.

[32]

Growth hormone responses to GH-releasing peptide (GHRP-6) in hypothyroidism.

Clinical endocrinology, 1997 Mar. human clinical.

[33]

Different effects of growth hormone releasing peptide (GHRP-6) and GH-releasing hormone on GH release in endogenous and exogenous hypercortisolism.

Clinical endocrinology, 1997 Jun. human clinical.

[34]

Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation.

The Journal of clinical endocrinology and metabolism, 1998 Apr. human clinical.

[35]

Preserved growth hormone (GH) secretion in aged and very old subjects after testing with the combined stimulus GH-releasing hormone plus GH-releasing hexapeptide-6.

The Journal of clinical endocrinology and metabolism, 1998 Jul. human clinical.

[36]

Drugs@FDA/openFDA query for GHRP-6

U.S. Food and Drug Administration / openFDA. database query.

[37]

Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act

U.S. Food and Drug Administration, 2026-05-14. regulatory.

[38]

United Pharmacy MARCS-CMS 553916 - February 11, 2019

U.S. Food and Drug Administration, 2019-02-11. regulatory.

[39]

Compounding and the FDA: Questions and Answers

U.S. Food and Drug Administration. official guidance.

[40]

The 2026 List of Prohibited Substances and Methods

World Anti-Doping Agency, 2026. regulatory.